Skip to Content

Quest Diagnostics Inc DGX Stock Quote

| Rating as of

Morningstar‘s Stock Analysis DGX

Currency in USD
Is it the right time to buy or sell?
Is it the right time to buy or sell?

1-Star Price


5-Star Price


Economic Moat


Capital Allocation


With COVID-19 Headwinds Gathering, We've Modestly Lowered Our Fair Value Estimate for Quest

Debbie S. Wang Senior Equity Analyst

Business Strategy and Outlook

| Debbie S. Wang |

Quest Diagnostics has positioned itself as the leading provider of independent diagnostic testing in the U.S. by building out a network of roughly 2,300 patient service centers across the country. We think Quest's size and cost advantage allows it to benefit from several secular trends, including the proliferation of diagnostic tests and greater clinical reliance on personalized therapies. Additionally, we expect that through the intermediate term, Medicare-related pricing pressure should ease as regulators tinker with the method for setting lab test reimbursement rates.

Unlock Our Full Analysis With Morningstar Investor

Key Statistics DGX

Company Profile DGX

Business Description

Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.

500 Plaza Drive
Secaucus, NJ, 07094
T +1 973 520-2700
Industry Diagnostics & Research
Most Recent Earnings Jun 30, 2022
Fiscal Year End Dec 31, 2022
Employees 49,000

Related News DGX